1Leucht S,Wahlbeck K,Hamann J,et al.New generation antipsychotics versus low-potencyconventional antipsychotics:a systematic review and meta-analysis[J].Lancet,2003,361(9 369):1 581.
2Leucht S,Barnes TRE,Kissling W,et al.Relapse prevention in schizophrenia with new-generation antipsychotics:a systematic review and exploratory metaanalysis of randomized,controlled trials[J].Am J Psychiatry,2003,160(6):1 209.
3Davis JM,Chen N,Glick ID.A meta-analysis of the efficacy of second-generation antipsychotics[J].Arch Gen Psychiatry,2003,60 (3):553.
4Bagnall AM,Jones L,Ginnelly L,etal.A systematic review of atypical antipsychotic drugs in schizophrenia[J].Health Technol Assess,2003,7(1):1.
5Correll CU,Leucht S,Kane JM.Lower risk for tardive dyskinesias associated with second-generation antipsychotics:a systematic review of 1-year studies[J].Am J Psychiatry,2004,161(3):414.
6Hennen J,Baldessarini RJ.Reduced suicidal risk during treatment with clozapine:A meta-analysis[J].Schizophr Res,2005,73(2):139.
7Lehman AF,Lieberman JA,Dixon LB,et al.Practice guideline for the treatment of patients with schizophrenia,second edition[J].Am J Psychiatry,2004,161(Suppl 2):1.
8Hirose S.The causes of underdiagnosing akathisia[J].Schizophr Bull,2003,29(5):547.
9Tarsy D,Baldessarini RJ,Tarazi FI.Effects of newer antipsychotics on extrapyramidal function[J].CNS Drugs,2002,16(1):23.
10Harvey P D, Bowie C R. Ziprasidone: efticacy, tolerability, and emerging data on wide ranging effectiveness. Expert Opin Pharmacother, 2005,6(2) :337
